Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04054765 · ClinicalTrials.gov registry record · NA
A Virtual Reality Videogame for E-cigarette Prevention in Teens
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 287
- Enrollment target
NCT04054765: Completed NA study, sponsored by Yale University.
NCT04054765 is a NA study that has completed, run by Yale University. The registered enrollment target is 287 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04054765, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 287 participants
- Enrollment target
Study Summary
The use of the Invite Only VR, with the aim to prevent the initiation of e-cigarette use in teens by increasing their knowledge, decreasing their intentions to use e-cigarettes, influencing their harm perceptions and attitudes associated with e-cigarettes, and increasing self-efficacy associated with refusing peers involving e-cigarettes.
Primary Outcome
The researcher will measure the percent of individuals who, after playing Invite Only VR, report the initiation of e-cigarette use in comparison to the control condition.
Interventions
- OTHER treatment as usual
- DEVICE videogame
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2020-06-05 |
| Phase | NA |
What the finished NCT04054765 record still lists
NCT04054765 is an interventional study that assigns participants to a tested intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which treatment as usual is the first listed.
NCT04054765 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04054765 about?
NCT04054765 is a clinical study titled "A Virtual Reality Videogame for E-cigarette Prevention in Teens". The use of the Invite Only VR, with the aim to prevent the initiation of e-cigarette use in teens by increasing their knowledge, decreasing their intentions to use e-cigarettes, influencing their harm perceptions and attitudes associated with e-cigarettes, and increasing self-efficacy associated wit...
What is the current status of trial NCT04054765?
This trial is currently completed. It is a NA study. The enrollment target is 287 participants. The study started on 2019-10-17. Estimated completion is 2020-06-05.
What interventions are being tested in trial NCT04054765?
The interventions under investigation include: treatment as usual (OTHER), videogame (DEVICE).
Who is sponsoring clinical trial NCT04054765?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04054765's enrollment target sits among peer trials
287 377th of 2000 higher than 1,624 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI